Marzia Del Re

Marzia Del Re is an Associate Professor at the Department of Faculty Medicine, Saint Camillus International University of Health and Medical Sciences (Rome, Italy), and affiliated with Fondazione Policlinico A. Gemelli IRCCS. Her research focuses on pharmacogenetic analysis of germline DNA for adverse drug reactions and circulating nucleic acids to monitor tumor resistance. She holds a Pharm.D. (2009) and a PhD in Clinical Pathophysiology (2018) from the University of Pisa. Notable awards include the American Society of Clinical Oncology Merit Awards (2011, 2013) for work on DPYD variants. She has held visiting roles at Erasmus Medical Center (Netherlands), NIH (USA), and Mount Sinai Hospital (USA). Her expertise spans liquid biopsy applications, drug resistance mechanisms, and multidisciplinary clinical guidelines.

Education:

• Pharm.D., University of Pisa (2009)
• Specialist in Clinical Biochemistry, University of Pisa (2014)
• Master’s in Clinical Trials in Oncology, University of Pisa (2015)
• Ph.D. in Clinical Pathophysiology, University of Pisa (2018)

Research Interests: Pharmacogenetics, liquid biopsy for tumor monitoring, EGFR/ALK mutation-driven therapies, and drug resistance in lung/prostate cancers. Her work has influenced national guidelines for fluoropyrimidine treatment and liquid biopsy integration in oncology practice.

Awards:

• American Society of Clinical Oncology Merit Award (2011)
• American Society of Clinical Oncology Merit Award (2013)
• Multiple awards for pharmacogenetic research

Advancing Care: Member of AIOM and SIF panels for clinical guidelines. Pioneered DPYD testing for fluoropyrimidine safety. Collaborated on liquid biopsy protocols at international institutions. Co-authored consensus papers on metastatic prostate, breast, and lung cancers.

Labs/Teams: Involved in Molecular Tumor Boards, liquid biopsy validation projects (e.g., LB-RECIST criteria), and translational research at the Tisch Cancer Institute and MSKCC.